A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide

Inclusion Criteria:

• Must have a histologically or cytologically-confirmed diagnosis of adenocarcinoma ofthe prostate

• Must have documented metastatic hormone-sensitive prostate cancer (mHSPC)

• Must have agreed with the treating physician the initiation of either apalutamide orenzalutamide (plus androgen deprivation therapy [ADT]) treatment, per the treatingphysician's decision, prior to enrollment into the study

• Must sign, and/or their legally acceptable representative where applicable mustsign, a participation agreement/ informed consent form (ICF) allowing datacollection and source data verification in accordance with local requirements

• Must have baseline prostate-specific antigen (PSA) captured within 30 days prior tothe first administration of apalutamide or enzalutamide

• Must agree to complete patient-reported outcomes (PROs) during the study, includingthe baseline ones collected before the first administration of apalutamide orenzalutamide

Exclusion Criteria:

• Has already received or is currently receiving either apalutamide or enzalutamide,or any other novel hormonal treatments (including but not limited to abirateroneacetate and darolutamide)

• Is currently receiving an active treatment for prostate cancer as part of aninterventional study

• Has a progression under ADT treatment (and thus became castrate-resistant) prior tostart of apalutamide or enzalutamide treatment

• Has received ADT treatment for mHSPC for more than 2 months prior to apalutamide orenzalutamide treatment initiation or ADT treatment was administered for earlierdisease stages within the last 12 months prior to apalutamide or enzalutamidetreatment initiation

• Has received prior docetaxel for the treatment of mHSPC

• Participants is not treated in line with current Summary of Product Characteristicsfor apalutamide or enzalutamide